Limitations and future treatment options in type 2 diabetes with renal impairment.
作者信息
Ritz Eberhard
机构信息
Department of Internal Medicine, Nierenzentrum, Im Neuenheimer Feld, Heidelberg, Germany.
出版信息
Diabetes Care. 2011 May;34 Suppl 2(Suppl 2):S330-4. doi: 10.2337/dc11-s242.
Abstract
摘要
相似文献
1
Limitations and future treatment options in type 2 diabetes with renal impairment.
Diabetes Care. 2011 May;34 Suppl 2(Suppl 2):S330-4. doi: 10.2337/dc11-s242.
2
Guidelines and clinical practice at the primary level of healthcare in patients with type 2 diabetes mellitus with and without kidney disease in five European countries.
Diab Vasc Dis Res. 2019 Jan;16(1):47-56. doi: 10.1177/1479164118795559. Epub 2018 Sep 21.
3
Angiotensin blockade in type 2 diabetic renal disease.
Kidney Int Suppl. 2002 Dec(82):S61-3. doi: 10.1046/j.1523-1755.62.s82.12.x.
4
Renin angiotensin system (RAS) blockade and diabetic microvascular complications in the eye and kidney.
Prim Care Diabetes. 2008 Dec;2(4):201-2. doi: 10.1016/j.pcd.2008.06.002. Epub 2008 Aug 28.
5
[Inhibition of the renin-angiotensin system in type 2 diabetes. New significant results concerning type 2 diabetes and renal disease].
Ugeskr Laeger. 2001 Oct 1;163(40):5488.
6
Microvascular benefits of hypertension and glucose control in type 2 diabetes.
Cardiovasc J Afr. 2008 Jul-Aug;19(4):179-80.
7
Renin-angiotensin-aldosterone system blockade and urinary albumin excretion in community-based patients with Type 2 diabetes: the Fremantle Diabetes Study.
Diabet Med. 2011 Jul;28(7):849-55. doi: 10.1111/j.1464-5491.2011.03230.x.
8
The glucagon-like peptide-1 receptor agonist, liraglutide, attenuates the progression of overt diabetic nephropathy in type 2 diabetic patients.
Tohoku J Exp Med. 2013 Sep;231(1):57-61. doi: 10.1620/tjem.231.57.
9
Effect of addition of silymarin to renin-angiotensin system inhibitors on proteinuria in type 2 diabetic patients with overt nephropathy: a randomized, double-blind, placebo-controlled trial.
Am J Kidney Dis. 2012 Dec;60(6):896-903. doi: 10.1053/j.ajkd.2012.06.005. Epub 2012 Jul 7.
10
Klotho protein supplementation reduces blood pressure and renal hypertrophy in db/db mice, a model of type 2 diabetes.
Acta Physiol (Oxf). 2019 Feb;225(2):e13190. doi: 10.1111/apha.13190. Epub 2018 Oct 16.
引用本文的文献
1
Evaluation of Effect of Montelukast in the Model of Streptozotocin Induced Diabetic Nephropathy in Rats.
Indian J Endocrinol Metab. 2024 Jan-Feb;28(1):47-54. doi: 10.4103/ijem.ijem_414_22. Epub 2024 Feb 26.
2
Telemedicine assists in the management of proatherogenic dyslipidemia and postprandial glucose variability in patients with type 2 diabetes mellitus: a cross-sectional study.
Endocr Connect. 2021 Jul 21;10(7):789-795. doi: 10.1530/EC-21-0209.
3
Assessment of Second-Generation Diabetes Medication Initiation Among Medicare Enrollees From 2007 to 2015.
JAMA Netw Open. 2020 May 1;3(5):e205411. doi: 10.1001/jamanetworkopen.2020.5411.
4
Comparison of vildagliptin and sitagliptin in patients with type 2 diabetes and severe renal impairment: a randomised clinical trial.
Diabetologia. 2015 Sep;58(9):2020-6. doi: 10.1007/s00125-015-3655-z. Epub 2015 Jun 12.
5
Management of patients with type 2 diabetes and mild/moderate renal impairment: profile of linagliptin.
Ther Clin Risk Manag. 2015 May 14;11:799-805. doi: 10.2147/TCRM.S67076. eCollection 2015.
6
Pharmacokinetics and clinical use of incretin-based therapies in patients with chronic kidney disease and type 2 diabetes.
Clin Pharmacokinet. 2015 Jan;54(1):1-21. doi: 10.1007/s40262-014-0198-2.
7
The effects of GLP-1 analogues, DPP-4 inhibitors and SGLT2 inhibitors on the renal system.
Diab Vasc Dis Res. 2014 Sep;11(5):306-23. doi: 10.1177/1479164114542802.
8
Direct action of endothelin-1 on podocytes promotes diabetic glomerulosclerosis.
J Am Soc Nephrol. 2014 May;25(5):1050-62. doi: 10.1681/ASN.2013020195. Epub 2014 Apr 10.
9
Safety and efficacy of linagliptin in type 2 diabetes patients with common renal and cardiovascular risk factors.
Ther Adv Endocrinol Metab. 2013 Jun;4(3):95-105. doi: 10.1177/2042018813486165.
10
Diabetic nephropathy.
Clin Med (Lond). 2012 Oct;12(5):480-2; quiz 483-5. doi: 10.7861/clinmedicine.12-5-480.
本文引用的文献
1
Selective vitamin D receptor activation with paricalcitol for reduction of albuminuria in patients with type 2 diabetes (VITAL study): a randomised controlled trial.
Lancet. 2010 Nov 6;376(9752):1543-51. doi: 10.1016/S0140-6736(10)61032-X.
2
Strict glycaemic control in diabetic patients with CKD or ESRD: beneficial or deadly?
Nephrol Dial Transplant. 2010 Jul;25(7):2044-7. doi: 10.1093/ndt/gfq199. Epub 2010 Apr 12.
3
Acute kidney injury: a springboard for progression in chronic kidney disease.
Am J Physiol Renal Physiol. 2010 May;298(5):F1078-94. doi: 10.1152/ajprenal.00017.2010. Epub 2010 Mar 3.
4
Avosentan for overt diabetic nephropathy.
J Am Soc Nephrol. 2010 Mar;21(3):527-35. doi: 10.1681/ASN.2009060593. Epub 2010 Feb 18.
5
Endothelin receptor antagonists in proteinuric renal disease: every rose has its thorn.
J Am Soc Nephrol. 2010 Mar;21(3):392-4. doi: 10.1681/ASN.2010010047. Epub 2010 Feb 4.
6
Follow-up of phase I trial of adalimumab and rosiglitazone in FSGS: III. Report of the FONT study group.
BMC Nephrol. 2010 Jan 29;11:2. doi: 10.1186/1471-2369-11-2.
7
Cerebral microvascular disease predicts renal failure in type 2 diabetes.
J Am Soc Nephrol. 2010 Mar;21(3):520-6. doi: 10.1681/ASN.2009050558. Epub 2010 Jan 28.
8
Glycemic control and cardiovascular events in diabetic hemodialysis patients.
Circulation. 2009 Dec 15;120(24):2421-8. doi: 10.1161/CIRCULATIONAHA.109.857268.
9
Addition of angiotensin receptor blockade or mineralocorticoid antagonism to maximal angiotensin-converting enzyme inhibition in diabetic nephropathy.
J Am Soc Nephrol. 2009 Dec;20(12):2641-50. doi: 10.1681/ASN.2009070737. Epub 2009 Nov 19.
10
Strict blood-pressure control and progression of renal failure in children.
N Engl J Med. 2009 Oct 22;361(17):1639-50. doi: 10.1056/NEJMoa0902066.
Zotero 插件